Sphera Funds Management LTD. Has $2.59 Million Holdings in Leap Therapeutics Inc (LPTX)

Sphera Funds Management LTD. decreased its position in Leap Therapeutics Inc (NASDAQ:LPTX) by 33.4% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 332,525 shares of the company’s stock after selling 166,612 shares during the period. Sphera Funds Management LTD.’s holdings in Leap Therapeutics were worth $2,590,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Millennium Management LLC purchased a new stake in Leap Therapeutics in the 1st quarter valued at about $105,000. JPMorgan Chase & Co. purchased a new stake in Leap Therapeutics in the 3rd quarter valued at about $111,000. DRW Securities LLC purchased a new stake in Leap Therapeutics in the 2nd quarter valued at about $347,000. Point72 Asset Management L.P. increased its stake in Leap Therapeutics by 178.0% in the 2nd quarter. Point72 Asset Management L.P. now owns 75,888 shares of the company’s stock valued at $683,000 after buying an additional 48,588 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in Leap Therapeutics by 24.7% in the 2nd quarter. Renaissance Technologies LLC now owns 112,467 shares of the company’s stock valued at $1,012,000 after buying an additional 22,247 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Shares of LPTX stock opened at $3.17 on Friday. Leap Therapeutics Inc has a 12-month low of $3.13 and a 12-month high of $10.25.

Leap Therapeutics (NASDAQ:LPTX) last issued its quarterly earnings results on Thursday, November 15th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.02). On average, analysts expect that Leap Therapeutics Inc will post -2.37 earnings per share for the current fiscal year.

LPTX has been the subject of several research analyst reports. Zacks Investment Research upgraded shares of Leap Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 price target for the company in a research note on Wednesday, August 15th. ValuEngine upgraded shares of Leap Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 30th. Finally, HC Wainwright set a $13.00 price target on shares of Leap Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, October 23rd.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.com-unik.info/2018/12/08/sphera-funds-management-ltd-has-2-59-million-holdings-in-leap-therapeutics-inc-lptx.html.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.

Further Reading: Find a Trading Strategy That Works

Want to see what other hedge funds are holding LPTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Leap Therapeutics Inc (NASDAQ:LPTX).

Institutional Ownership by Quarter for Leap Therapeutics (NASDAQ:LPTX)

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit